Member Info for AndytheMKDon

Take it back up, they were relentless in dragging it down..

Rns was as expected. What's becoming increasingly clear is how well Chk1 is progressing, we tend to overlook it as its a work in progress and not as sexy as an announcement on one or more of the other compounds. However, it's the equivalent of being 1-0 at halftime and we've just put another couple of players on the pitch, Tyk 2 etc could be great going forwards but Chk1 has the prospect of being great very soon. ;+) Glass 3/4 full. Gla. Andy.

Last line VERY important.. !! Sounds to me as if this initial tranche might be the only one, but hey who knows. Well done to Jarv and uinsionn for efforts in getting a reply from them. :+)

Dr Zed.. I'm hoping it's nothing negative but my honest feeling is for nothing more than the usual annual update with a bit of progress being made on fronts other than Chk1. We all know from history that expectations can be built up only to be dashed, and most of the good news here has come unexpectedly rather than in scheduled publications such as company results and annual updates, maybe Tim will excel tis year..lol. Monday is my guess for the RNS.

I get it and you've made the point of your feelings on the CLN's but to keep repeating it is a bit dull. I don't have your history here so no idea if you have lost money, I guess you must have given the vitriol you have for the BOD and Nomad. However for me and probably others it's a new investment based upon a stock looking oversold and a company with near term revenue streams, albeit with short term cash needs. I've seen the scenario many times before where company's have used CLN's as a type of bridging loan but then cancelled them and the future need for them as their cash position improved. Some of these are now vibrant and profitable companies, you probably know some yourself. I don't wish you any malice but simply want you to recognise that not everybody sees this company as the crock of ****e that you do. Gl fella and I hope your investment comes through. Andy.

Do you hold shares here?? If so I can't understand you dissing the company and your investment. If you hold no shares what's your motive?? Good Samaritan?? Soothsayer??Doomster?? Trader?? Wear your pants over the top of your trousers superman style?? Bit confused fella on why you spend hours banging the same drum..

Guerrillas in the mist.. Gorilla's are dangerous but not as dangerous as the Guerrillas who have talked and pulled this down over the last days..

Enthusiasm and Tim Mitchell being mentioned in the same sentence is a bit of a euphemism.. lol. Have you met him??

Short traders have made their dollars as have the mm's.. Can't wring the sponge out anymore..

??

All supposition buddy.. Nobody will ever figure out the way of the world on aim. I'm simply following the principal if a companies price has been pulled down like this one has there's normally money being made, then the greedy buggers make money on the up-train too..

You seem to have it in for this company fella.. !! The technical suggest oversold and a gap to be filled..

Here comes the bounce.. Leveraged positions closed??

Humble pie coming up on main course. Lol.

8m more buys than sells and pull it down 17.5%.. You have to laugh.. jokers will walk it back when they've done their laundry..

Time to buy when everyone selling!! By the way the buy volume today is 21M and the sell volume is 13M so please keep your posts accurate fella. :+)

Like you I put a toe in the water here today.. As you say a modest bounce will offer up some quick gains..

2m trades x 2 and 1.5m x 1.. Looks oversold to me..

Hey buddy, I hope you are well. SAR going forwards will be cash generative based upon royalty payments alone, also we have projects which have not yet been put into trials but will be soon. So there is a possibility of somebody taking SAR over simply to acquire the patents and IPR at an early stage for a cheap price rather than at a later stage at potentially a much higher price. Sierra would become a target and probably are a target based upon Chk1 alone as they hold the worldwide licensing agreement with SAR / CRT and ICR earning royalties in the event of a viable product being developed. So there is a case is for them to be bought separately or maybe Sierra take SAR and somebody in the future takes Sierra, one thing for sure is if there is a viable and effective product developed for the cancers targeted, the two entities SAR and Sierra will be worth billions not millions. Yes it is still a big if, but as more progress is made and it appears no negatives have surfaced, the value of the companies increases, even if at this moment the share price of SAR doesn't reflect it. GL. Andy. Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, is pleased to announce that its co-investment partner, the CRT Pioneer Fund, has today licensed exclusive and worldwide rights for the Chk1 inhibitor cancer drug candidate CCT245737 (to be renamed PNT737) to ProNAi Therapeutics, Inc. (NASDAQ: DNAI). Under the terms of the agreement, an immediate upfront payment of US$7.0 million is due to the co-investment partners and an additional fee of up to US$2.0 million will be payable upon the successful transfer of the two ongoing Phase 1 clinical trials to ProNAi. Additional payments in the aggregate amount of up to US$319.5 million may become payable upon achievement of certain development, regulatory and commercial milestones. ProNAi will also owe high single to low double digit royalties on the net sales of any product successfully developed. Under Sareum's agreements with Cancer Research Technology and the CRT Pioneer Fund, Sareum is entitled to 27.5% of these payments. Therefore, Sareum will receive (i) US$1.9 million as an upfront payment, (ii) potential future milestone payments of up to US$88.4 million, some of which are expected to be paid within the next twelve months upon certain development milestones being met and (iii) its share of any sales royalties.

It appears the trials have progressed well, so much so they are now expanding the number of people to receive treatment. They are also widely expanding the number of cancers they are targeting, among them some of the most common cancers, prostate, lung, ovarian, bowel and others. The progress so far suggests our Chk1 is out performing that of Lilly's, given Lilly's resources compared to those of Sierra, it's remarkable that some of the large pharma's are not interested in Sierra / SAR, or are they? Maybe they were waiting to see if the first hurdles could be jumped and now they have been there now appears to be a much more compelling argument for one of the big boys to pick up this progress and run with it. My feeling is its only a question of when Sierra and SAR are acquired not if.